Search

Your search keyword '"Parati, Maria Chiara"' showing total 23 results
Start Over Author "Parati, Maria Chiara" Publication Year Range Last 50 years
23 results on '"Parati, Maria Chiara"'

4. Different Chemotherapy Regimens and Pathologic Complete Response in Triple-Negative Breast Cancer: An Updated Network Meta-Analysis of Phase 3 Trials

Author

Petrelli, Fausto, primary, Tomasello, Gianluca, additional, Parati, Maria Chiara, additional, Ghidini, Antonio, additional, Ghidini, Michele, additional, Borgonovo, Karen, additional, Cabiddu, Mary, additional, Ghilardi, Mara, additional, Reduzzi, Roberto, additional, Gambini, Donatella, additional, Zaniboni, Alberto, additional, Faustinelli, Giovanni, additional, and Garrone, Ornella, additional

Published
2024
Full Text
View/download PDF

11. Vitamin D3 and COVID-19 Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses

Author

Petrelli, Fausto, primary, Oldani, Simone, additional, Borgonovo, Karen, additional, Cabiddu, Mary, additional, Dognini, Giuseppina, additional, Ghilardi, Mara, additional, Parati, Maria Chiara, additional, Petro’, Daniela, additional, Dottorini, Lorenzo, additional, Rea, Carmen, additional, Lonati, Veronica, additional, Luciani, Andrea, additional, and Ghidini, Antonio, additional

Published
2023
Full Text
View/download PDF

13. Outcome of non-small-cell lung cancer with driven mutations treated with anti-PD-(L)1 agents: A systematic review

Author

Luciani, Andrea, Ghidini, Antonio, Borgonovo, Karen, Parati, Maria Chiara, and Petrelli, Fausto

Abstract

Patients whose tumours harbour epidermal growth factor receptor (EGFR), and anaplastic lymphoma kinase (ALK) driver mutations can benefit most from treatment with tyrosine kinase inhibitors (TKIs). Most trials with immune checkpoint inhibitors (ICIs) included few patients whose tumour had oncogenic driver alterations. We therefore performed a meta-analysis of studies reporting the activity of ICIs in oncogene addicted NSCLC. A comprehensive search of MEDLINE, The Cochrane Library and EMBASE was conducted to identify relevant studies published up to 31 January 2021. The primary outcomes were median overall survival (OS); the secondary endpoints were progression-free survival and overall response rate (PFS and ORR). Overall, 46 studies were screened and selected for final analysis. The pooled ORR was 14.5% (95% CI 9.6-21.2%). The median pooled PFS in EGFR/ALK mutated cases was 3.9 months (95% CI 3-5.2 months). Median pooled OS was 10.7 months (95% CI 9.2-12.5 months). All registration trials in second line did not show any benefit of immunotherapy for the subgroup of patients with EGFR-mutated or ALK-rearranged tumours. The unsatisfied benefit of immunotherapy in oncogene-addicted tumours has been debated and is mainly due to the lower mutation burden of these neoplasms. Our data do not support the use of immunotherapy in the setting of oncogene actionable tumours. More data are needed to confirm or reject the benefit of the combination of TKIs with ICIs.

Published
2023
Full Text
View/download PDF

15. Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection

Author

Parati, Maria Chiara, primary, Pedersini, Rebecca, additional, Perego, Gianluca, additional, Reduzzi, Roberto, additional, Savio, Tommaso, additional, Cabiddu, Mary, additional, Borgonovo, Karen, additional, Ghilardi, Mara, additional, Luciani, Andrea, additional, and Petrelli, Fausto, additional

Published
2022
Full Text
View/download PDF

21. Immune-related adverse events (irAEs) and survival in solid tumors treated with immune checkpoint inhibitors (ICIs): A systematic review and meta-analysis.

Author

Grizzi, Giulia, primary, Petrelli, Fausto, additional, Ghidini, Michele, additional, Ghidini, Antonio, additional, Ratti, Margherita, additional, Panni, Stefano, additional, Cabiddu, Mary, additional, Ghilardi, Mara, additional, Borgonovo, Karen, additional, Parati, Maria Chiara, additional, Barni, Sandro, additional, Tomasello, Gianluca, additional, Passalacqua, Rodolfo, additional, Berruti, Alfredo, additional, and Brighenti, Matteo, additional

Published
2019
Full Text
View/download PDF

23. Lactobacillus Kefiri LKF01 (Kefibios ®) for Prevention of Diarrhoea in Cancer Patients Treated with Chemotherapy: A Prospective Study.

Author

Ghidini, Michele, Nicoletti, Mariaceleste, Ratti, Margherita, Tomasello, Gianluca, Lonati, Veronica, Ghilardi, Mara, Parati, Maria Chiara, Borgonovo, Karen, Cabiddu, Mary, Petrelli, Fausto, Barker, Tyler, and Artale, Salvatore

Abstract

Diarrhoea is one of the main side effects that cancer patients face. The literature showsthat the incidence of chemotherapy (CT)-induced diarrhoea (grade 3–4) in treated patients is in the range of 10–20%, particularly after 5-fluorouracil (5-FU) bolus or some combination therapies of irinotecan and fluoropyrimidines. The aim of the present study was to evaluate the clinical effectiveness of Lactobacillus kefiri LKF01 (Kefibios®) in the prevention or treatment of CT-related diarrhoea in the cancer population. We conducted a prospective observational study. Patients enrolled were adults treated for at least four months with 5-FU-based CT. Kefibios® was administered to patients every day. The primary outcome was the evaluation of the incidence of grade 3–4 CT-induced diarrhoea. We included 76 patients in the final analysis. A 6.6% incidence of high-grade diarrhoea was found in the evaluated population (4.7% of patients treated with 5-FU-based therapy and 8.5% of patients treated with capecitabine-based CT). The overall incidence of high-grade diarrhoea observed was higher in the 1st and 2nd cycles (3.9%), with a subsequent sharp reduction from the 3rd cycle (1.3%) and negativisation from the 5th cycle. Lactobacillus kefiri LKF01 (Kefibios®) is safe and effective in preventing severe diarrhoea in cancer patients receiving 5-FU or capecitabine-based treatment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results